<DOC>
	<DOCNO>NCT00033345</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Indole-3-carbinol may effective prevent breast cancer . PURPOSE : Phase I trial study effectiveness indole-3-carbinol preventing breast cancer nonsmoking woman high risk breast cancer .</brief_summary>
	<brief_title>Indole-3-Carbinol Preventing Breast Cancer Nonsmoking Women Who Are High Risk For Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability indole-3-carbinol prevention breast cancer non-smoking woman high risk breast cancer . - Determine pharmacokinetics drug participant . - Determine effect drug metabolites estrogen urine participant . - Determine additional effect drug select indicator drug metabolism reproductive hormonal function participant . - Assess possible antineoplastic activity drug participant . - Determine quality life participant receive drug . OUTLINE : This single-blind study . Participants ingest study compound twice daily week 1-12 1-16 . Study compound dispensed week 1 , 5 , 9 . At time , study compound oral placebo , time , oral indole-3-carbinol . Quality life assess baseline every 4 week study therapy . PROJECTED ACCRUAL : A total 18 participant accrue study within 9 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Indole-3-carbinol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Women high risk breast cancer , define least 1 follow criterion : Projected 5year probability invasive breast cancer least 1.66 % , determine Breast Cancer Risk Assessment Tool Prior nodenegative breast cancer Prior biopsy indicate atypical lobular ductal hyperplasia carcinoma situ Age 60 Nonsmoker confirm urine cotinine test No concurrent breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Premenopausal ( regular menstrual cycle 2436 day within past 6 month ) OR Postmenopausal ( menstrual cycle least 6 month ) Performance status : Not specify Life expectancy : At least 1 year Hematopoietic : Absolute granulocyte count great 1,500/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 1.8 mg/dL Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) less 110 U/L Alkaline phosphatase le 300 U/L Albumin great 3 g/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : No acute unstable cardiovascular condition base electrocardiogram Other : Mild seasonal allergy allow No serious lifethreatening drug allergies No serious intolerance allergies No 20 % ideal body weight No acute unstable medical condition physical examination laboratory test No chronic headache , dysphoria , fatigue , dizziness , blur vision , insomnia , rhinorrhea , nausea , vomit , abdominal pain , diarrhea , constipation , similar condition No serious illness require chronic drug therapy No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 1 month , , 1 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : At least 2 month since prior hormonal therapy contraception hormone replacement therapy ( HRT ) No concurrent sex hormone contraception premenopausal woman No concurrent HRT postmenopausal woman Radiotherapy : Not specify Surgery : Not specify Other : At least 6 month since prior investigational drug At least 1 month since prior weekly consumption 3 medium serving ( half cup ) cruciferous vegetables No concurrent vegetarian diet weekly consumption 3 medium serving ( half cup ) cruciferous vegetables No continuous supplement intake No recent change medication dosage medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>